Do analysts rate AIXC or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 541.37%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, AIXC or DWTX?

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is AIXC or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Dogwood Therapeutics N/A -108.57% -30.28%

Do analysts prefer AIFC or AIXC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, AIFC or AIXC?

Qualigen Therapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 2.33 -$344.51M N/A N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Do analysts prefer INKT or AIXC?

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 217.81%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, INKT or AIXC?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is INKT or AIXC more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Qualigen Therapeutics N/A -771.52% -79.52%

Do analysts recommend AIXC or EDSA?

Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 7.58%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher earnings & valuation, AIXC or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is AIXC or EDSA more profitable?

Edesa Biotech's return on equity of -286.52% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Edesa Biotech N/A -286.52% -75.36%

Do analysts recommend AIXC or INCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIXC or INCR more profitable?

InterCure's return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% InterCure N/A N/A N/A

Qualigen Therapeutics (AIXC) Competitors

$0.77 -0.02 (-2.77%)

As of 02:56 PM Eastern

Compare

AIXC vs. DWTX, AIFC, INKT, EDSA, and INCR

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Dogwood Therapeutics (DWTX), ALT5 Sigma (AIFC), MiNK Therapeutics (INKT), Edesa Biotech (EDSA), and InterCure (INCR).

How does Qualigen Therapeutics compare to Dogwood Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Dogwood Therapeutics (NASDAQ:DWTX) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Qualigen Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 541.37%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Dogwood Therapeutics'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Dogwood Therapeutics	Neutral

Dogwood Therapeutics' return on equity of -108.57% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Summary

Dogwood Therapeutics beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Qualigen Therapeutics (NASDAQ:AIXC) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Qualigen Therapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	2.33	-$344.51M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ALT5 Sigma had 3 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for ALT5 Sigma and 0 mentions for Qualigen Therapeutics. ALT5 Sigma's average media sentiment score of 0.47 beat Qualigen Therapeutics' score of 0.00 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Qualigen Therapeutics	Neutral

ALT5 Sigma has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Qualigen Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ALT5 Sigma beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Qualigen Therapeutics (NASDAQ:AIXC) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, MiNK Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Qualigen Therapeutics	Neutral

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 217.81%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MiNK Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Summary

MiNK Therapeutics beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Edesa Biotech?

Qualigen Therapeutics (NASDAQ:AIXC) and Edesa Biotech (NASDAQ:EDSA) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Edesa Biotech had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Edesa Biotech	Neutral

Edesa Biotech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 7.58%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Qualigen Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Edesa Biotech's return on equity of -286.52% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Edesa Biotech	N/A	-286.52%	-75.36%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Edesa Biotech beats Qualigen Therapeutics on 12 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to InterCure?

Qualigen Therapeutics (NASDAQ:AIXC) and InterCure (NASDAQ:INCR) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

InterCure's return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
InterCure	N/A	N/A	N/A

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
InterCure	Neutral

Qualigen Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, InterCure has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

InterCure has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
InterCure	$78.47M	0.67	-$10.37M	$0.03	31.93

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InterCure beats Qualigen Therapeutics on 8 of the 9 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIXC vs. The Competition

Export

Metric	Qualigen Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$15.08M	$15.52B	$29.68B	$13.01B
Dividend Yield	N/A	3.45%	2.76%	10.03%
P/E Ratio	-0.12	131.21	81.85	25.51
Price / Sales	N/A	1,288.58	597.91	116.02
Price / Cash	N/A	40.66	45.04	34.82
Price / Book	-1.02	8.31	8.08	6.35
Net Income	-$16.97M	$437.13M	$663.37M	$347.60M
7 Day Performance	-6.99%	2.11%	4.76%	3.14%
1 Month Performance	-30.36%	-0.23%	-1.30%	-2.08%
1 Year Performance	N/A	7.71%	151.95%	21.27%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIXC Qualigen Therapeutics	0.0671 of 5 stars	$0.77 -2.8%	N/A	N/A	$15.08M	N/A	N/A	50	Positive News Gap Down
DWTX Dogwood Therapeutics	2.5339 of 5 stars	$1.54 -0.6%	$12.00 +679.2%	-64.7%	$51.79M	N/A	N/A	5	News Coverage
AIFC ALT5 Sigma	0.3829 of 5 stars	$0.37 -5.8%	N/A	-93.7%	$51.70M	$24.84M	N/A	170
INKT MiNK Therapeutics	2.541 of 5 stars	$10.38 -1.5%	$35.00 +237.2%	-27.4%	$51.69M	N/A	N/A	30
EDSA Edesa Biotech	0.867 of 5 stars	$5.36 +7.8%	$5.00 -6.7%	+144.4%	$51.62M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. DWTX, AIFC, INKT, EDSA, and INCR

How does Qualigen Therapeutics compare to Dogwood Therapeutics?

Summary

How does Qualigen Therapeutics compare to ALT5 Sigma?

Summary

How does Qualigen Therapeutics compare to MiNK Therapeutics?

Summary

How does Qualigen Therapeutics compare to Edesa Biotech?

Summary

How does Qualigen Therapeutics compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. DWTX, AIFC, INKT, EDSA, and INCR

How does Qualigen Therapeutics compare to Dogwood Therapeutics?

Which has better valuation and earnings, AIXC or DWTX?

Which has more volatility and risk, AIXC or DWTX?

Do insiders and institutionals hold more shares of AIXC or DWTX?

Do analysts rate AIXC or DWTX?

Does the media refer more to AIXC or DWTX?

Is AIXC or DWTX more profitable?

Summary

How does Qualigen Therapeutics compare to ALT5 Sigma?

Which has preferable valuation & earnings, AIFC or AIXC?

Do insiders & institutionals have more ownership in AIFC or AIXC?

Does the media prefer AIFC or AIXC?

Which has more volatility and risk, AIFC or AIXC?

Is AIFC or AIXC more profitable?

Do analysts prefer AIFC or AIXC?

Summary

How does Qualigen Therapeutics compare to MiNK Therapeutics?

Does the media refer more to INKT or AIXC?

Do analysts prefer INKT or AIXC?

Which has more volatility & risk, INKT or AIXC?

Do institutionals & insiders have more ownership in INKT or AIXC?

Is INKT or AIXC more profitable?

Which has higher valuation & earnings, INKT or AIXC?

Summary

How does Qualigen Therapeutics compare to Edesa Biotech?

Does the media refer more to AIXC or EDSA?

Which has higher earnings & valuation, AIXC or EDSA?

Do analysts recommend AIXC or EDSA?

Which has more volatility & risk, AIXC or EDSA?

Is AIXC or EDSA more profitable?

Do institutionals and insiders believe in AIXC or EDSA?

Summary

How does Qualigen Therapeutics compare to InterCure?

Is AIXC or INCR more profitable?

Does the media favor AIXC or INCR?

Which has more risk & volatility, AIXC or INCR?

Which has higher valuation and earnings, AIXC or INCR?

Do institutionals & insiders believe in AIXC or INCR?

Do analysts recommend AIXC or INCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools